Ligasure Hemorrhoidectomy Versus Open Hemorrhoidectomy
Launched by HOLBAEK SYGEHUS · Oct 23, 2019
Trial Information
Current as of May 01, 2025
Unknown status
Keywords
ClinConnect Summary
Background
Hemorrhoids is one of the oldest known medical conditions. Description of hemorrhoids is found as early as 2250 Before Christ (BC) in the code of king Hammurabi in Babylon. Even though first recorded treatment is thought to be found in the "Edwin Smith Papyrus" from 1700 BC as of today the treatment of this benign state is still debated. A wide range of prevalence rates of hemorrhoids have been stated in part because of the varying definition ,but the general consensus is that hemorrhoidal disease is a common anorectal disease affecting the quality of life of millions of people ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has Grade III-IV haemorrhoids or Grade II haemorrhoids with bleeding resistant to rubber band ligation or sclerotherapy
- • The patient has a Haemorrhoidal Symptom Score of 4 or more
- • The patient has an American Society of Anaesthesiologists (ASA) score I-II
- • The patient's age is 18-85 years at inclusion
- • The patient has had a colonoscopy, sigmoidoscopy or rigid rectoscopy within 3 months before inclusion
- Exclusion Criteria:
- • The patient has had previous operation for haemorrhoids within the last 2 years
- • The patient has had previous operation for anal incontinence
- • The patient has an active anal fistula
- • The patient has an active anal fissure
- • The patient has anal incontinence for solid stools
- • Active immunosuppressive therapy (increased risk of anorectal sepsis)
- • Cirrhosis / portal hypertension
- • Mb Crohn.
About Holbaek Sygehus
Holbæk Sygehus, a leading healthcare institution in Denmark, is dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a strong emphasis on collaboration and ethical practice, the hospital provides a robust infrastructure for conducting a diverse range of studies across various therapeutic areas. Holbæk Sygehus is committed to fostering a patient-centered approach, ensuring that clinical trials not only contribute to scientific knowledge but also prioritize safety and well-being. Through its experienced research team and state-of-the-art facilities, Holbæk Sygehus plays a pivotal role in the development of new therapies and enhancements in clinical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Holbaek, , Denmark
Patients applied
Trial Officials
Per Olov Gunnar Olaison, MD, pHD
Study Director
Department of Surgery, Holbaek County Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials